Osprey Pharmaceuticals USA, a San Francisco-based developer of protein therapeutics for treating inflammatory diseases, has raised $11 million in first-round funding. Burrill & Co. led the round, and was joined by Novo Nordisk Biotech Fund, Yasuda Enterprise Development, GeneChem Therapeutics Venture Fund, BDC Venture Capital, Inc. and Western Technology Seed Investment Fund.
